The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review describes the modern data concerning the cellular and molecular mechanisms of mineral metabolism disturbance in bone tissue. Cytokine system consisting of receptor activator of nuclear factor к-b, its ligand and osteoprotegerin (RANKL/RANK/OPG) has a key role in understanding of bone remodeling regulation. We discuss a significance of the cytokine system in osteoblasto- and osteoclastogenesis. Molecular processes of histogenesis and bone resorption have been analyzed.

Full Text

Restricted Access

About the authors

D. S Aganov

S.M. Kirov Military Medical Academy

Saint-Petersburg, Russia

V. V Tyrenko

S.M. Kirov Military Medical Academy

Saint-Petersburg, Russia

E. N Tsygan

S.M. Kirov Military Medical Academy

Saint-Petersburg, Russia

M. M Toporkov

S.M. Kirov Military Medical Academy

Saint-Petersburg, Russia

S. G Bologov

S.M. Kirov Military Medical Academy

Saint-Petersburg, Russia

References

  1. Franklin J., Englund M., Ingvarsson T. The association between hip fracture and hip osteoarthritis: A case-control study. BMC Musculoskelet. Disord. 2010; 11(1): 274.
  2. Торопцова Н.В., Михайлов Е.Е., Беневоленская Л.И. Проблема остеопороза в современном мире. Росс. мед. журн. 2005; 13(24): 1582-5.
  3. Cooper C., Atkinson E.J., Jacobsen S.J. et al. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 1993; 137(9): 1001-5.
  4. Bliuc D., Nguyen N.D., Milch V.E. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5): 513-21.
  5. Olszynski W.P., Shawn Davison K., Adachi J.D. et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin. Ther. 2004; 26(1): 15-28.
  6. Cameron D.A. The biochemistry and physiology of bone. The ultrastructure of bone 2012; 1: 191-236.
  7. Riggs B.L. The pathogenesis of involutional osteoporosis. Seventh Bath Conference on Osteoporosis, UK. Osteoporosis Int. 2000; 11 Suppl 1: 1-20
  8. Аничков Н.М., Дергунов А.В., Цыган В.Н. и др. Патофизиология обмена веществ. Санкт-Петербург: СпецЛит; 2013.
  9. Papaioannou A., Morin S., Cheung A.M. et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can. Med. Assoc. J. 2010; 182(17): 1864-73.
  10. Reddi A.H., Roodman D., Freeman C. et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J. Bone Miner. Res. 2003; 18 (2): 190-4.
  11. Raska O., Bernaskova K. Bone metabolism: a note on the significance of mouse models. Physiol. Res. 2009; 58: 459-71.
  12. Belanger L., Leonard F., Migicovsky B. Histochemical evidence of proteolysis in bone: the influence of parathormone. J. Histochem. Cytochem. 1963; 11(6): 734-7.
  13. Цыган Е.Н., Деев Р.В. Морфофункциональные основы остеопороза. Санкт-Петербург: ВМедА; 2007.
  14. Bianco P., Fisher L.W., Young M.F. et al. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int. 1991; 49(6): 421-6.
  15. Walsh M.C., Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Inflammation 2014; 5: 511.
  16. Lacey D.L., Dunstan C.R., Kelley M. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89 (2): 309-19.
  17. Tsuda E., Goto M., Mochizuki S.I. et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Bioph. Res. Co. 1997; 234(1): 137-42.
  18. Lacey D.L., Timms E., Tan H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2): 165-76.
  19. Yasuda H.,Shima N., Nakagawa N.et al.Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS USA. 1998; 95(7): 3597-602.
  20. Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2): 309-19.
  21. Kadono Y., Okada F., Perchonock C. et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep. 2005; 6(2): 171-6.
  22. Wada T, Nakashima T, Oliveira-Dos-Santos A. et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 2005; 11(4): 394-9.
  23. Wang X.F., Zhang Y.K., Yu Z.S., Zhou J.L. The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients. Mol. Med. Rep. 2013; 7(4): 1169-72.
  24. Wong B., Josien R., Lee Y. et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 1998; 273(43): 28355-9.
  25. Жоголев К.Д, Никитин В.Ю, Цыган Е.Н. и др. Регуляция остеогенеза и иммуногенеза репаративных процессов. Санкт-Петербург: ВМедА, 2003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies